 Intercept Pharmaceuticals Inc NASDAQ: ICPT has withdrawn its European marketing application seeking approval for obeticholic acid OCA for liver fibrosis due to nonalcoholic steatohepatitis NASH. The initial application was filed in December 2019 was supported by the interim analysis results from the Phase 3 REGENERATE study, which remains ongoing. 